Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality and underscore the importance of integrated cardio-oncology care.
Abstract
Background Despite increasing evidence on the bi-directional association between cancer and atherosclerotic cardiovascular disease (ASCVD), less is known about differences in mortality among individuals with co-existing diseases. Objective We examined all-cause and disease-specific mortality among U.S. adults living with cancer, ASCVD, and co-existing cancer and ASCVD. Methods Among adults aged ≥18 years in the National Health Interview Survey (2005-2018) linked to the National Death Index (through December 31, 2019), we estimated multivariable-adjusted HRs (aHRs) and 95% CIs using Cox proportional hazards models. Mortality outcomes were compared across individuals with cancer alone, ASCVD alone, and co-existing conditions, relative to those with neither condition. Results Among 388,632 individuals, 1.3% had co-existing cancer and ASCVD, representing approximately 3.0 million U.S. adults annually. Over a mean follow-up of 7.2 years, co-existing disease was associated with the highest all-cause mortality (aHR, 2.45 [95% CI: 2.23-2.70]), exceeding ASCVD alone (aHR, 1.93 [1.82-2.04]) and cancer alone (aHR, 1.90 [1.77-2.04]). Co-existing disease was associated with elevated risks of both cancer mortality (aHR, 4.18 [3.48-5.03]) and cardiovascular mortality (aHR, 2.73 [2.30-3.24]). Among those living with co-existing diseases, older age (≥75 years) (aHR, 6.02 [1.97-18.37]), diabetes (aHR, 1.23 [1.03-1.46]), and current/former smoking status (aHR, 1.26 [1.07-1.49]) were associated with increased hazards of all-cause mortality. Conclusions Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality. These findings highlight the elevated burden of mortality among individuals with co-existing cancer and ASCVD and underscore the importance of integrated cardio-oncology care.
Cancer remains a leading cause of mortality globally, while hypertension is the primary contributor to cardiovascular disease and premature death. These conditions frequently coexist; hypertension may precede cancer due to shared risk factors or arise during or after cancer treatment, partly as a result of the hyperten...
Bahaa Mali, Ali Mali, Alaa Mali et al.· Scientific Reports· 0 citations
The overall AAMR declined substantially over the 25-year study period, with the most pronounced reductions occurring in the mid-2000s, followed by a marked deceleration after 2019, which highlighted the need for targeted equitable access to guideline-directed vascular care.
Pre-existing CVD at cancer diagnosis has increased substantially over 2 decades and is projected to affect nearly half of patients by 2050, which underscores the need for the expansion of cardio-oncology services.
A. Alshahrani, E. Kontopantelis, C. Morgan et al.· European Heart Journal· 0 citations
Background: Type 2 diabetes (T2D) is associated with elevated rates of several cancers and is increasingly recognized as a heterogeneous disease, but whether its clinically distinct subtypes carry different cancer risks is unknown. Methods: In this matched retrospective cohort study using electronic health record data...
Z. Li, C. Liu, M. B. Weber et al.· medRxiv· 0 citations
Background Breast cancer remains a major cause of cancer mortality among older adults in the United States. Although overall breast cancer mortality has declined in recent decades, the extent to which these improvements have been shared across demographic and geographic subgroups among adults aged 65 years and older re...
Tong Feng, Peng-Cheng Zheng, Qing-Yuan Li et al.· Frontiers in Oncology· 0 citations
Despite declining overall CRC mortality, recent increases were observed in several metastatic and noncancer contributing conditions, and model-based projections indicate that overall lung metastasis mortality will continue to increase through 2040, whereas liver metastasis mortality will peak in 2028 and subsequently d...
Zi-Chen He, Ya-Dong Chen, Yu-Xing Hu et al.· Frontiers in Public Health· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.